Cipla yesterday said that it has received final approval from the US health regulator for Arformoterol Tartrate Inhalation Solution, used to treat conditions like chronic bronchitis and emphysema, in the US market.
The approved product is a generic version of Sunovion Pharmaceuticals Inc’s Brovana.
The company has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL from the United States Food and Drug Administration (FDA), Cipla said in a regulatory filing.
Brovana is used in the maintenance treatment of bronchoconstriction in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema.
Quoting IQVIA (IMS Health) data, Cipla said Brovana had sales of approximately $438 million for the 12-month period ending April 2021.
The product is available for shipping immediately, it added.
When it comes to hair care, many of us are constantly on the lookout for…
Cheese is a beloved food around the globe, with people enjoying it in countless forms,…
A recent Zika virus case has emerged in Gandhinagar, Gujarat, marking a significant milestone in…
A recent study conducted by researchers at the University of Leeds, UK, has found significant…
Hashimoto's disease, recently highlighted by Bollywood actor Arjun Kapoor as a condition he’s battling, is…
Beware of counterfeit salt: The consumption of counterfeit salt, with its unreliable composition and low…